title: Mir-221/222 are promising targets for innovative anticancer therapy.
abstract: BACKGROUND
  MicroRNAs (miRNAs) are key non-coding RNA post-transcriptional regulators of messenger RNAs (mRNAs), and are deeply dysregulated in human cancer. A rising body of evidence indicates that miRNAs represent valuable therapeutic targets. In this light, the cluster miR-221/222 are of particular relevance, given that they are strongly upregulated in a variety of solid and hematologic malignancies.
  
  
  METHODS
  This review summarizes recent findings on the roles played by miR-221/222 in human cancer and their potential clinical value as promising targets for therapeutic studies.
  
  
  CONCLUSIONS
  The rising body of advanced preclinical evidence on the biological significance of miR-221/222 in a variety of malignancies indicates that they will play a crucial role in the future of innovative therapeutic strategies, both as validated biomarkers and targets.
authors.affiliation: a Department of Experimental and Clinical Medicine , Magna Graecia University, Salvatore Venuta University Campus , Catanzaro , Italy.
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Di Martino
authors.affiliation: a Department of Experimental and Clinical Medicine , Magna Graecia University, Salvatore Venuta University Campus , Catanzaro , Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Rossi
authors.affiliation: a Department of Experimental and Clinical Medicine , Magna Graecia University, Salvatore Venuta University Campus , Catanzaro , Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Caracciolo
authors.affiliation: a Department of Experimental and Clinical Medicine , Magna Graecia University, Salvatore Venuta University Campus , Catanzaro , Italy.
authors.forename: Annamaria
authors.initials: A
authors.lastname: Gullà
authors.affiliation: a Department of Experimental and Clinical Medicine , Magna Graecia University, Salvatore Venuta University Campus , Catanzaro , Italy.
authors.forename: Pierosandro
authors.initials: P
authors.lastname: Tagliaferri
authors.affiliation: a Department of Experimental and Clinical Medicine , Magna Graecia University, Salvatore Venuta University Campus , Catanzaro , Italy.|b Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology , Temple University , Philadelphia , PA , USA.
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Tassone
mesh_terms: D000818:Animals; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D012323:RNA Processing, Post-Transcriptional / Q000235:genetics; D022661:RNA, Untranslated / Q000235:genetics; D015854:Up-Regulation
chemical_list: D035683:MicroRNAs; D022661:RNA, Untranslated; C525709:MIR221, human; C525710:MIR222, human
keywords: MicroRNA; cancer; miR-221; miR-221/222; miRNA; miRNA inhibitors; myeloma; oligonucleotide-based therapy